Universal Beteiligungs und Servicegesellschaft mbH Increases Position in Axsome Therapeutics, Inc. $AXSM

Universal Beteiligungs und Servicegesellschaft mbH increased its holdings in Axsome Therapeutics, Inc. (NASDAQ:AXSM) by 30.7% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 67,902 shares of the company’s stock after acquiring an additional 15,934 shares during the quarter. Universal Beteiligungs und Servicegesellschaft mbH owned approximately 0.14% of Axsome Therapeutics worth $8,247,000 as of its most recent filing with the SEC.

Other hedge funds have also recently bought and sold shares of the company. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. grew its stake in Axsome Therapeutics by 4.8% during the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 21,923 shares of the company’s stock valued at $2,557,000 after purchasing an additional 1,002 shares in the last quarter. Jones Financial Companies Lllp boosted its stake in shares of Axsome Therapeutics by 2,407.9% during the 1st quarter. Jones Financial Companies Lllp now owns 7,624 shares of the company’s stock valued at $889,000 after buying an additional 7,320 shares during the last quarter. Goldman Sachs Group Inc. grew its position in shares of Axsome Therapeutics by 38.7% during the first quarter. Goldman Sachs Group Inc. now owns 301,718 shares of the company’s stock worth $35,189,000 after buying an additional 84,151 shares in the last quarter. Caxton Associates LLP acquired a new stake in shares of Axsome Therapeutics during the first quarter worth approximately $307,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC increased its stake in shares of Axsome Therapeutics by 29.9% in the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 74,892 shares of the company’s stock worth $8,735,000 after buying an additional 17,250 shares during the last quarter. Institutional investors and hedge funds own 81.49% of the company’s stock.

Axsome Therapeutics Trading Down 0.5%

NASDAQ:AXSM opened at $185.96 on Monday. The firm has a market capitalization of $9.37 billion, a P/E ratio of -39.82, a P/E/G ratio of 9.80 and a beta of 0.44. The business has a 50 day simple moving average of $159.39 and a 200 day simple moving average of $133.42. The company has a debt-to-equity ratio of 1.66, a current ratio of 1.57 and a quick ratio of 1.50. Axsome Therapeutics, Inc. has a 12-month low of $86.99 and a 12-month high of $191.50.

Axsome Therapeutics (NASDAQ:AXSM) last issued its earnings results on Monday, November 3rd. The company reported ($0.94) earnings per share for the quarter, missing the consensus estimate of ($0.82) by ($0.12). Axsome Therapeutics had a negative return on equity of 277.31% and a negative net margin of 40.90%.The company had revenue of $170.99 million during the quarter, compared to analyst estimates of $162.96 million. The firm’s revenue was up 63.2% compared to the same quarter last year. Equities research analysts predict that Axsome Therapeutics, Inc. will post -2.79 EPS for the current year.

Insider Activity

In other news, CFO Nick Pizzie sold 12,000 shares of Axsome Therapeutics stock in a transaction that occurred on Thursday, January 22nd. The stock was sold at an average price of $187.92, for a total transaction of $2,255,040.00. Following the sale, the chief financial officer owned 42,588 shares of the company’s stock, valued at approximately $8,003,136.96. The trade was a 21.98% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is accessible through the SEC website. Also, CEO Herriot Tabuteau sold 31,261 shares of the business’s stock in a transaction that occurred on Wednesday, January 7th. The stock was sold at an average price of $170.38, for a total value of $5,326,249.18. Following the transaction, the chief executive officer owned 7,229 shares of the company’s stock, valued at approximately $1,231,677.02. This represents a 81.22% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. In the last quarter, insiders have sold 440,403 shares of company stock valued at $67,191,178. 22.40% of the stock is owned by company insiders.

Key Headlines Impacting Axsome Therapeutics

Here are the key news stories impacting Axsome Therapeutics this week:

• Positive Sentiment: Piper Sandler is bullish ahead of a likely Auvelity label expansion by April 30, which would expand the approved uses for Axsome’s depression drug and could materially increase addressable market and sales expectations. Piper Sandler Bullish on Axsome Therapeutics (AXSM) Ahead of Likely Auvelity Label Expansion by April 30
• Positive Sentiment: HC Wainwright has increased some earnings estimates and reiterated a Buy rating with a $260 target, signaling conviction in Axsome’s medium-term revenue trajectory and valuation upside. This analyst support is likely propping up investor sentiment despite volatility. HC Wainwright Brokers Increase Earnings Estimates for AXSM
• Positive Sentiment: Related coverage from HC Wainwright and other outlets highlights expectations for strong price appreciation and has coincided with recent share strength, providing momentum that could support further gains if clinical and label catalysts materialize. HC Wainwright Forecasts Strong Price Appreciation for Axsome Therapeutics (NASDAQ:AXSM) Stock
• Positive Sentiment: Axsome recently hit a new 12‑month high following analyst upgrades, reflecting elevated optimism from the sell side which can attract momentum and institutional interest. Axsome Therapeutics (NASDAQ:AXSM) Hits New 12-Month High Following Analyst Upgrade
• Neutral Sentiment: Analyst roundup pieces summarize diverse views from ~14 analysts; consensus leans positive but shows dispersion in price targets and timing, indicating investor outcomes depend heavily on upcoming regulatory/label and sales data. 3AXSM : Expert Outlook: Axsome Therapeutics Through The Eyes Of 14 Analysts
• Negative Sentiment: HC Wainwright’s detailed model changes are mixed — while they raised several quarterly and FY2025 estimates and the target, they also trimmed forecasts for certain quarters (notably Q2 and Q3 adjustments). That mix introduces near-term earnings uncertainty that can create volatility until clinical/label outcomes and actual sales datapoints arrive.

Wall Street Analysts Forecast Growth

AXSM has been the topic of a number of research analyst reports. Needham & Company LLC reiterated a “buy” rating and set a $225.00 price objective on shares of Axsome Therapeutics in a research note on Monday, January 5th. Mizuho set a $217.00 price target on shares of Axsome Therapeutics in a research report on Wednesday, December 31st. TD Cowen reiterated a “buy” rating on shares of Axsome Therapeutics in a research note on Wednesday, December 31st. Guggenheim reissued a “buy” rating and issued a $205.00 price objective on shares of Axsome Therapeutics in a report on Friday, January 2nd. Finally, Piper Sandler increased their target price on Axsome Therapeutics from $148.00 to $223.00 and gave the stock an “overweight” rating in a report on Friday, January 16th. Nineteen research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat.com, the stock has an average rating of “Moderate Buy” and a consensus price target of $203.17.

Axsome Therapeutics Profile

Axsome Therapeutics, Inc is a clinical-stage biopharmaceutical company dedicated to developing novel therapies for central nervous system (CNS) disorders. The company focuses on small-molecule drugs designed to address unmet medical needs in areas such as depression, migraine, narcolepsy and fibromyalgia. Axsome employs a precision medicine approach, leveraging pharmacologic innovation to target underlying mechanisms of disease and improve patient outcomes.

Axsome’s pipeline includes several late-stage and approved product candidates.